Year: 2011
Type: article
Abstract: Increasing evidence supports the role of intracellular Aß oligomerization as an early event in the pathogenesis of Alzheimer's Disease in humans and in transgenic mice, but little is known about the intracellular processing and trafficking events of the different forms of AßOs. Here, we propose the use of intracellular antibodies (intrabodies) to dissect the cellular pathways leading to AßOs formation and actions, exploiting new conformational anti-AßOs antibody fragments (Meli et al., J. Mol. Biol. 2009), which are suitable for intracellular expression. The use of specific conformational intrabodies allows interfering in cells with post-translationally modified, or processed, proteins (as APP and its products Aß/AßOs) in a way that cannot be performed with the RNAi-based methods. In this study, we propose an intrabody-mediated targeting of AßOs in cultured cells. The intracellular expression of the anti-AßOs intrabodies was performed in a well established cell model for AßOs production and secretion, referred to as 7PA2 cells (Walsh et al., Nature, 2002), generating cells stably transfected with intrabodies in different formats. The in vivo binding and the modulation of AßOs generation were studied by analysis of cellular media and by experiments of sub cellular fractionation and intrabody-AßOs pull-down. The anti-AßOs intrabodies targeted to specific intracellular compartments act as specific interference tools. In particular, we performed the specific and selective sub cellular targeting of AßOs in the Endoplasmic Reticulum (ER), through the expression of an intrabody with an ER retention signal (KDEL). The use of derivative KDEL form of an anti-AßOs intrabody shows: i) the efficacy in AßOs-binding, trapping and retargeting in specific ER compartments; ii) the ability to selectively reduce the secretion of small AßOs; iii) no interference in the post-translational maturation of the Aß precursor protein (APP). The specific sub cellular localization of anti-AßOs intrabodies and their efficacy in vivo in AßOs-binding, trapping and in the reduction of AßOs secreted shows that Aß principally do not oligomerize post-secretion, but intracellularly. Thus, intracellular AßOs are a relevant target for new therapeutics. We confirmed the anti-AßOs intrabodies as unique tool to study the intracellular Aß oligomerization and also to be exploited as new diagnostics and therapeutics.
Source: Alzheimer s & Dementia
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: intrabodies, amyloid-beta oligomers
Open Access status: bronze
OpenAlex ID: W2015097657
